(Q44561169)

4 December 2017

title

DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals (English)

1 reference

4 December 2017

Damian Wild

1

1 reference

4 December 2017

Jörg S Schmitt

2

1 reference

4 December 2017

Mihaela Ginj

3

1 reference

4 December 2017

Helmut R Mäcke

4

1 reference

4 December 2017

Bert F Bernard

5

1 reference

4 December 2017

Eric Krenning

6

1 reference

4 December 2017

Marion De Jong

7

1 reference

4 December 2017

Sandra Wenger

8

1 reference

4 December 2017

Jean-Claude Reubi

9

1 reference

4 December 2017

publication date

21 August 2003

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

4 December 2017

published in

1 reference

4 December 2017

volume

30

1 reference

4 December 2017

issue

10

1 reference

4 December 2017

page(s)

1338-1347

1 reference

https://scigraph.springernature.com/pub.10.1007/s00259-003-1255-5

4 December 2017

exact match

0 references

cites work

DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy

1 reference

12 December 2020

Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.

1 reference

12 December 2020

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

1 reference

12 December 2020

Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours

1 reference

12 December 2020

99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals.

1 reference

12 December 2020

Human ovarian cancers express somatostatin receptors

1 reference

12 December 2020

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

1 reference

12 December 2020

Established clinical use of octreotide and lanreotide in oncology

1 reference

12 December 2020

Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging

1 reference

12 December 2020

The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours

1 reference

12 December 2020

Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy.

1 reference

12 December 2020

1 reference

12 December 2020

Expression of human somatostatin receptor subtype 3 in pancreatic cancer in vitro and in vivo

1 reference

12 December 2020

Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE)

1 reference

12 December 2020

Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC

1 reference

12 December 2020

Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy

1 reference

12 December 2020

Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue

1 reference

12 December 2020

Yttrium-90-labelled somatostatin-analogue for cancer treatment

1 reference

12 December 2020

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

1 reference

12 December 2020

A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors

1 reference

12 December 2020

Radiolabelled peptides: now and the future.

1 reference

12 December 2020

Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management

1 reference

12 December 2020

Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829

1 reference

12 December 2020

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

1 reference

12 December 2020

Small peptides radiolabeled with 99mTc.

1 reference

12 December 2020

Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization

1 reference

12 December 2020

Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors

1 reference

12 December 2020

Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

1 reference

12 December 2020

The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules

1 reference

12 December 2020

Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy

1 reference

12 December 2020

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy

1 reference

12 December 2020

A ticket to ride: peptide radiopharmaceuticals.

1 reference

12 December 2020

Yttrium-90 DOTATOC: first clinical results

1 reference

12 December 2020

Fates of endocytosed somatostatin sst2 receptors and associated agonists

1 reference

12 December 2020

Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy

1 reference

12 December 2020

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives

1 reference

12 December 2020

NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors

1 reference

12 December 2020

Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy.

1 reference

12 December 2020

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

1 reference

12 December 2020

Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors--evaluation of therapeutic and toxic effects

1 reference

12 December 2020

Diagnostic applications of radiolabeled peptides in nuclear endocrinology.

1 reference

12 December 2020

Receptor targeting for tumor localisation and therapy with radiopeptides

1 reference

12 December 2020

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

1 reference

12 December 2020

Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management

1 reference

12 December 2020

111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors

1 reference

12 December 2020

111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung

1 reference

12 December 2020

10.1007/S00259-003-1255-5

Identifiers

DOI

1 reference

4 December 2017

1 reference